SCHEMBL3612459

SCHEMBL3612459

COC1(OC)CCN(C(=O)OC(C)(C)C)CC1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ESR2 Q92731 1/20 0.41
MAPK1 P28482 1/20 0.40
CYP11B2 P19099 1/20 0.38
ADORA1 P30542 1/20 0.38
MAPT P10636 3/20 0.37
USP30 Q70CQ3 1/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736466 0.83 ESR2 (0.47) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL18087311 0.83 USP2 (0.45) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL17369319 0.80 USP2 (0.42) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL4774218 0.80 USP30 (0.43) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL18838278 0.80 USP30 (0.43) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL3618965 0.79 CYP2C19 (0.33) USP2MAPK1ALDH1A1TSHR
SCHEMBL31391827 0.78 NR1H2 (0.40) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL3658167 0.78 MAPK1 (0.42) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL17761048 0.78 MAPK1 (0.42) NR1H2USP2SMN1; SMN2ESR2MAPK1
SCHEMBL16914261 0.78 USP30 (0.44) NR1H2USP2SMN1; SMN2ESR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304574-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES Pathios Therapeutics Limited (GB) 2025-10-02 US disclosed
WO-2023187391-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES Pathios Therapeutics Limited (GB) 2023-10-05 WO disclosed
WO-2015034729-A1 SUBSTITUTED PYRIDINE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-03-12 WO disclosed
US-20100286181-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2010-11-11 US disclosed
CN-101558066-A Pyrrole derivatives with antibacterial activity ASTRAZENECA AB (SE) 2009-10-14 CN disclosed
EP-2064209-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2009-06-03 EP disclosed
WO-2008020222-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286181-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY PGLS, UROD, GMPS NR1H2 3711/4885USP2 4056/4885SMN1; SMN2 4040/4885
US-20250304574-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES GPR65, GPR52, GPR68 NR1H2 5/4885USP2 4107/4885SMN1; SMN2 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.